GB201223386D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB201223386D0
GB201223386D0 GBGB1223386.2A GB201223386A GB201223386D0 GB 201223386 D0 GB201223386 D0 GB 201223386D0 GB 201223386 A GB201223386 A GB 201223386A GB 201223386 D0 GB201223386 D0 GB 201223386D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1223386.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune UK Ltd
Original Assignee
Immune Targeting Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Targeting Systems Ltd filed Critical Immune Targeting Systems Ltd
Priority to GBGB1223386.2A priority Critical patent/GB201223386D0/en
Publication of GB201223386D0 publication Critical patent/GB201223386D0/en
Priority to ES13814593T priority patent/ES2906110T3/es
Priority to KR1020157020103A priority patent/KR102358621B1/ko
Priority to CN202111025902.7A priority patent/CN114028553A/zh
Priority to DK13814593.3T priority patent/DK2935313T3/da
Priority to CA2895459A priority patent/CA2895459A1/en
Priority to JP2015548778A priority patent/JP6811014B2/ja
Priority to PCT/GB2013/053410 priority patent/WO2014102540A1/en
Priority to EA201591213A priority patent/EA201591213A1/ru
Priority to EP21201879.0A priority patent/EP3995146A1/en
Priority to KR1020237003896A priority patent/KR102625645B1/ko
Priority to US14/655,041 priority patent/US10300132B2/en
Priority to EP13814593.3A priority patent/EP2935313B1/en
Priority to KR1020227003308A priority patent/KR102497063B1/ko
Priority to PL13814593T priority patent/PL2935313T3/pl
Priority to CN201380067602.2A priority patent/CN104903343A/zh
Priority to JP2018189011A priority patent/JP7187237B2/ja
Priority to US16/423,149 priority patent/US11382969B2/en
Priority to JP2021025254A priority patent/JP7235785B2/ja
Priority to US17/861,189 priority patent/US11918645B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1223386.2A 2012-12-24 2012-12-24 Vaccine Ceased GB201223386D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine
CN201380067602.2A CN104903343A (zh) 2012-12-24 2013-12-20 抗乙型肝炎病毒的疫苗
EA201591213A EA201591213A1 (ru) 2012-12-24 2013-12-20 Вакцины против вируса гепатита b
KR1020237003896A KR102625645B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
CN202111025902.7A CN114028553A (zh) 2012-12-24 2013-12-20 包括免疫原性肽组合的药物组合物
DK13814593.3T DK2935313T3 (da) 2012-12-24 2013-12-20 Vacciner mod hepatitis B-virus
CA2895459A CA2895459A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
JP2015548778A JP6811014B2 (ja) 2012-12-24 2013-12-20 Ｂ型肝炎ウイルスに対するワクチン
PCT/GB2013/053410 WO2014102540A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
ES13814593T ES2906110T3 (es) 2012-12-24 2013-12-20 Vacunas contra el virus de la Hepatitis B
EP21201879.0A EP3995146A1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
KR1020157020103A KR102358621B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
US14/655,041 US10300132B2 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis B virus
EP13814593.3A EP2935313B1 (en) 2012-12-24 2013-12-20 Vaccines against hepatitis b virus
KR1020227003308A KR102497063B1 (ko) 2012-12-24 2013-12-20 B형 간염 바이러스에 대한 백신
PL13814593T PL2935313T3 (pl) 2012-12-24 2013-12-20 Szczepionki przeciwko wirusowi zapalenia wątroby typu b
JP2018189011A JP7187237B2 (ja) 2012-12-24 2018-10-04 Ｂ型肝炎ウイルスに対するワクチン
US16/423,149 US11382969B2 (en) 2012-12-24 2019-05-27 Vaccines against Hepatitis B virus
JP2021025254A JP7235785B2 (ja) 2012-12-24 2021-02-19 Ｂ型肝炎ウイルスに対するワクチン
US17/861,189 US11918645B2 (en) 2012-12-24 2022-07-09 Vaccines against hepatitis B virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1223386.2A GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine

Publications (1)

Publication Number Publication Date
GB201223386D0 true GB201223386D0 (en) 2013-02-06

Family

ID=47682590

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1223386.2A Ceased GB201223386D0 (en) 2012-12-24 2012-12-24 Vaccine

Country Status (12)

Country Link
US (3) US10300132B2 (enExample)
EP (2) EP2935313B1 (enExample)
JP (3) JP6811014B2 (enExample)
KR (3) KR102625645B1 (enExample)
CN (2) CN104903343A (enExample)
CA (1) CA2895459A1 (enExample)
DK (1) DK2935313T3 (enExample)
EA (1) EA201591213A1 (enExample)
ES (1) ES2906110T3 (enExample)
GB (1) GB201223386D0 (enExample)
PL (1) PL2935313T3 (enExample)
WO (1) WO2014102540A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) * 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
CN106610423A (zh) * 2015-10-26 2017-05-03 复旦大学 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CA3085492A1 (en) * 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
BR112020020323A2 (pt) * 2018-04-04 2021-01-05 Altimmune Inc Combinação de vacina, e, método para induzir uma resposta imune.
WO2020145901A1 (en) * 2019-01-11 2020-07-16 Agency For Science, Technology And Research Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
WO2020255018A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
PH12022550490A1 (en) * 2019-08-29 2023-02-06 Triad Nat Security Llc Hepatitis b virus vaccines
JP2023505304A (ja) * 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー．ヴイ． Ｂ型肝炎ウイルスに関連する疾患の治療
AU2021205936A1 (en) * 2020-01-09 2022-07-21 The Wistar Institute Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same
EP4161644A2 (en) * 2020-06-08 2023-04-12 F. Hoffmann-La Roche AG Anti-hbv antibodies and methods of use
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
JP3566284B2 (ja) * 1991-08-26 2004-09-15 ザ スクリップス リサーチ インスティテュート Ｂ型肝炎ウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド類
CA2168583C (en) * 1993-08-02 2007-10-02 Francis V. Chisari Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
CN1454082A (zh) 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
GB201022147D0 (en) 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine

Also Published As

Publication number Publication date
KR102625645B1 (ko) 2024-01-15
JP7187237B2 (ja) 2022-12-12
JP6811014B2 (ja) 2021-01-13
EP2935313B1 (en) 2021-11-24
JP2019034946A (ja) 2019-03-07
KR20150098676A (ko) 2015-08-28
US20200016263A1 (en) 2020-01-16
KR102358621B1 (ko) 2022-02-03
KR20220019846A (ko) 2022-02-17
KR20230021771A (ko) 2023-02-14
JP2021098711A (ja) 2021-07-01
KR102497063B1 (ko) 2023-02-06
US10300132B2 (en) 2019-05-28
CN114028553A (zh) 2022-02-11
CA2895459A1 (en) 2014-07-03
CN104903343A (zh) 2015-09-09
WO2014102540A1 (en) 2014-07-03
US20230090379A1 (en) 2023-03-23
DK2935313T3 (da) 2022-02-28
JP7235785B2 (ja) 2023-03-08
US20160106830A1 (en) 2016-04-21
EP3995146A1 (en) 2022-05-11
EP2935313A1 (en) 2015-10-28
JP2016505589A (ja) 2016-02-25
US11918645B2 (en) 2024-03-05
US11382969B2 (en) 2022-07-12
EA201591213A1 (ru) 2016-02-29
PL2935313T3 (pl) 2022-05-02
ES2906110T3 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
IL235890A0 (en) vaccine
DK2830816T3 (en) Hidtil ukendt coatingkoncept
DK3327112T3 (en) Agse-deficient stamme
PL2647387T3 (pl) Kompozycja szczepionki
GB201223386D0 (en) Vaccine
EP2935220A4 (en) PERI-carbinol
SG10201912291YA (en) Vaccine compositions
IL231043A (en) vaccine
ZA201500656B (en) Marker vaccine
EP2920142A4 (en) MÉTHANOFULLERRÈNES
GB201119999D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201120000D0 (en) Vaccine
DK2846829T3 (en) Vaccine combinations
GB201218407D0 (en) Adjuvants
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine
GB2515669B (en) Bacterial vaccine
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
GB201210088D0 (en) Odontalgic preparation
AU345893S (en) Treehouse
GB201216246D0 (en) Coolflip

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)